and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers’ (BMY) cancer medication Opdivo from the 10-product list ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback